Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Contract awarded to develop drug to protect against radiation-induced gastrointestinal injury

Date:  September 28, 2011

Company: RxBio Inc. of Johnson City, Tenn.

Contract amount: $15 million over two years

About this contract: RxBio Inc will study the efficacy of its drug Rx100, which may protect against radiation-induced gastrointestinal injury by interrupting programmed cell death, known as apoptosis. Preliminary data suggests that Rx100 can protect or mitigate injury and improve survival if administered up to 72 hours after deadly whole-body radiation exposure. The contract also supports development of manufacturing processes for the drug.

Additional information: BARDA is seeking additional proposals for products that potentially could treat or prevent illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident.  Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Press Release:  BARDA funds development of five drugs to protect against radiation

Procurement Announcement:  Contract Awarded under BAA-BARDA-09-34

PHE Newsroom

Submit an Inquiry

Watch, Listen, Subscribe

Twitter  LinkedIn  Facebook  Instagram

Watch us on YouTube  Follow us on Flickr  Subcribe to our RSS  Subscribe to our email list

  • This page last reviewed: August 05, 2020